Terms: = Prostate cancer AND BIRC3, AIP1, 330, ENSG00000023445, HIAP1, Q13489, MIHC, CIAP2, API2, cIAP2, MALT2, hiap-1, RNF49, HAIP1 AND Treatment
156 results:
1. Cognitive effects of long-term androgen deprivation therapy in older men with prostate cancer.
Pergolizzi D; Flaherty KR; Saracino RM; Root JC; Schofield E; Cassidy C; Katheria V; Patel SK; Dale W; Nelson CJ
Psychooncology; 2024 Mar; 33(3):e6336. PubMed ID: 38520472
[TBL] [Abstract] [Full Text] [Related]
2. Nonsurgical salvage options for locally recurrent prostate cancer after primary definitive radiotherapy: a systematic review and meta-analysis.
Yang J; Xiong X; Liao X; Zheng W; Xu H; Wei Q; Yang L
Int J Surg; 2024 May; 110(5):3008-3020. PubMed ID: 38348896
[TBL] [Abstract] [Full Text] [Related]
3. ARCHERY: a prospective observational study of artificial intelligence-based radiotherapy treatment planning for cervical, head and neck and prostate cancer - study protocol.
Aggarwal A; Court LE; Hoskin P; Jacques I; Kroiss M; Laskar S; Lievens Y; Mallick I; Abdul Malik R; Miles E; Mohamad I; Murphy C; Nankivell M; Parkes J; Parmar M; Roach C; Simonds H; Torode J; Vanderstraeten B; Langley R
BMJ Open; 2023 Dec; 13(12):e077253. PubMed ID: 38149419
[TBL] [Abstract] [Full Text] [Related]
4. Cost-Effectiveness Modeling of prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with prostate cancer in the United States.
Yee CW; Harvey MJ; Xin Y; Kirson NY
Pharmacoeconomics; 2024 Feb; 42(2):231-247. PubMed ID: 37934376
[TBL] [Abstract] [Full Text] [Related]
5. Risk of Short-Term prostate-Specific Antigen Recurrence and Failure in Patients With prostate cancer: A Secondary Analysis of a Randomized Clinical Trial.
Sayan M; Huang J; Xie W; Chen MH; Loffredo M; McMahon E; Orio P; Nguyen P; D'Amico AV
JAMA Netw Open; 2023 Oct; 6(10):e2336390. PubMed ID: 37801315
[TBL] [Abstract] [Full Text] [Related]
6. Radiation Therapy Changed the Second Malignancy Pattern in Rectal cancer Survivors.
Ye X; Tan Y; Ma R; Lou P; Yuan Y
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629753
[No Abstract] [Full Text] [Related]
7. Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: A systematic review and meta-analysis.
Leeman JE; Shin KY; Chen YH; Mak RH; Nguyen PL; D'Amico AV; Martin NE
Cancer; 2023 Oct; 129(19):3044-3052. PubMed ID: 37485697
[TBL] [Abstract] [Full Text] [Related]
8. Impact of Asian Race on Prognosis in De Novo Metastatic prostate cancer.
Ni X; Luu M; Ma W; Zhang T; Wei Y; Freedland SJ; Ye D; Daskivich TJ; Zhu Y
J Natl Compr Canc Netw; 2023 Jul; 21(7):733-741.e3. PubMed ID: 37433430
[TBL] [Abstract] [Full Text] [Related]
9. Inducing apoptosis by using microRNA in radio-resistant prostate cancer: an in-silico study with an in-vitro validation.
Darvish L; Bahreyni-Toossi MT; Aghaee-Bakhtiari SH; Firouzjaei AA; Amraee A; Tarighatnia A; Azimian H
Mol Biol Rep; 2023 Jul; 50(7):6063-6074. PubMed ID: 37294470
[TBL] [Abstract] [Full Text] [Related]
10. Salvage radiotherapy after radical prostatectomy: functional outcomes in the LAPPRO trial after 8-year follow-up.
Carlsson S; Bock D; Lantz A; Angenete E; Koss Modig K; Hugosson J; Bjartell A; Steineck G; Wiklund P; Haglind E
Scand J Urol; 2023 May; 58():11-19. PubMed ID: 37170656
[TBL] [Abstract] [Full Text] [Related]
11. Health litigation and cancer survival in patients treated in the public health system in a large Brazilian city, 2014-2019.
de Castro MSM; da Silva GDM; Figueiredo IVO; de Miranda WD; Magalhães Júnior HM; Dos Santos FP; de Sousa RP
BMC Public Health; 2023 Mar; 23(1):534. PubMed ID: 36944943
[TBL] [Abstract] [Full Text] [Related]
12. Infiltrating immune cells in prostate cancer tissue after androgen deprivation and radiotherapy.
Erlandsson A; Lundholm M; Watz J; Bergh A; Petrova E; Alamdari F; Helleday T; Davidsson S; Andren O; Tarish F
Int J Immunopathol Pharmacol; 2023; 37():3946320231158025. PubMed ID: 36880147
[TBL] [Abstract] [Full Text] [Related]
13. Association of Androgen Deprivation Therapy with Metabolic Disease in prostate cancer Patients: An Updated Meta-Analysis.
Swaby J; Aggarwal A; Batra A; Jain A; Seth L; Stabellini N; Bittencourt MS; Leong D; Klaassen Z; Barata P; Sayegh N; Agarwal N; Terris M; Guha A
Clin Genitourin Cancer; 2023 Jun; 21(3):e182-e189. PubMed ID: 36621463
[TBL] [Abstract] [Full Text] [Related]
14. treatment decision regret in long-term survivors after radical prostatectomy: a longitudinal study.
Meissner VH; Simson BW; Dinkel A; Schiele S; Ankerst DP; Lunger L; Gschwend JE; Herkommer K
BJU Int; 2023 May; 131(5):623-630. PubMed ID: 36545828
[TBL] [Abstract] [Full Text] [Related]
15. Efficacy of Novel Hormone Agents in the treatment of Metastatic Castration-resistant prostate cancer: A Real-world Retrospective Study.
Li JR; Wang SS; Chen CS; Yang CK; Lu K; Cheng CL; Hung SC; Chen SY; Hsu CY; Chiu KY
Anticancer Res; 2022 Oct; 42(10):4857-4866. PubMed ID: 36191989
[TBL] [Abstract] [Full Text] [Related]
16. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant prostate cancer Stratified by prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
Bögemann M; Shore ND; Smith MR; Tammela TLJ; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Lebret T; Schostak M; Verholen F; Le Berre MA; Srinivasan S; Ortiz J; Mohamed AF; Sarapohja T; Fizazi K
Eur Urol; 2023 Mar; 83(3):212-221. PubMed ID: 36089529
[TBL] [Abstract] [Full Text] [Related]
17. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.
Gu W; Han W; Luo H; Zhou F; He D; Ma L; Guo H; Liang C; Chong T; Jiang J; Chen Z; Wang Y; Zou Q; Tian Y; Xiao J; Huang J; Zhu S; Dong Q; Zhang X; Li H; Yang X; Chen C; Li J; Jin C; Zhang X; Ye D;
Lancet Oncol; 2022 Oct; 23(10):1249-1260. PubMed ID: 36075260
[TBL] [Abstract] [Full Text] [Related]
18. Incidence of genitourinary complications following radiation therapy for localised prostate cancer.
David RV; Kahokehr AA; Lee J; Watson DI; Leung J; O'Callaghan ME
World J Urol; 2022 Oct; 40(10):2411-2422. PubMed ID: 35951087
[TBL] [Abstract] [Full Text] [Related]
19. The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.
Landes JR; Moore SA; Bartley BR; Doan HQ; Rady PL; Tyring SK
J Cancer Res Clin Oncol; 2023 May; 149(5):2139-2155. PubMed ID: 35941226
[TBL] [Abstract] [Full Text] [Related]
20. Head-to-head comparison of
Huo H; Shen S; He D; Liu B; Yang F
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):16-24. PubMed ID: 35931759
[TBL] [Abstract] [Full Text] [Related]
[Next]
